Australia's most trusted
source of pharma news
Posted 7 May 2026 AM
The global downsizing of industry continues with BioNTech, the darling of the COVID-19 pandemic, slashing its manufacturing footprint - and 1860 jobs with it - along with much smaller trims by Gilead and Novartis this week.
In the face of diminishing sales of its Pfizer-partnered Covid vaccine, Comirnaty, BioNTech has decided to shutter manufacturing plants in Singapore and the German cities of Idar-Oberstein and Marburg. In addition, it will close the former headquarters of its CureVac subsidiary, also in Germany.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.